ArriVent BioPharma, Inc.
AVBP
$29.79
-$0.49-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.05% | -13.95% | -106.62% | -86.28% | -82.67% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 114.56% | 150.29% | 195.95% | 281.79% | 274.20% |
| Change in Net Operating Assets | -72.31% | -145.82% | -153.40% | -151.95% | -39.58% |
| Cash from Operations | -16.82% | -12.44% | -128.72% | -111.80% | -86.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.99% | 32.88% | 62.99% | -869.98% | -666.94% |
| Cash from Investing | 48.99% | 32.88% | 62.99% | -869.98% | -666.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 216.22% | 3,137.91% | 8.87% | -9.83% | -55.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 180.17% | 60.00% | -- | 96.05% | 85.38% |
| Cash from Financing | 217.92% | 3,158.65% | 8.83% | -9.21% | -55.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 122.55% | 104.57% | 62.21% | -220.27% | -232.00% |